In this prospective study on 377 patients, the authors evaluate the effect of the application of a patient-specific transcatheter heart valve (THV) selection algorithm, which suggests the use of a specific THV (CoreValve or SAPIEN XT) for specific anatomical subsets, on procedural outcomes.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
December 10, 2015
The study was a single-arm, multicentre, prospective study enrolling 31 high-risk adult individuals with symptomatic mitral regurgitation despite optimal medical therapy from five institutions in Europe. The primary efficacy endpoints included: (a) Technical success rate of the device implantation; (b) Technical feasibility of Cardioband adjustment;
December 7, 2015
Filmed at the 2015 EACTS Annual Meeting in Amsterdam, The Netherlands, this roundtable discussion focuses on current developments and technological improvements in valve surgery.
December 2, 2015
This video shows a right axillary Edwards SAPIEN 3 TAVR implanted through the new apical Certitude delivery system, in a patient with severe aortic stenosis. The postoperative follow-up was uneventful and the patient was discharged home on postoperative day three.
October 18, 2015
In this manuscript the authors report on the results of a retrospective propensity score analysis in 102 matched pairs of patients, considered to be in a “grey zone” of surgical risk for either TAVI (Edwards Sapiens, Medtronic CoreValve or Symetis Acurate TA prosthesis) or aortic valve replacement (AVR) with a sutureless prosthesis (Sorin Perceal).
October 8, 2015
The effects of renal failure on outcomes of AVR were examined using CMS data. TAVR pts on dialysis, TAVR pts not on dialysis, and surgical AVR pts on dialysis were compared after propensity score matching. In TAVR patients, dialysis was associated with increased 30 day mortality and survival, and was an independent predictor of worse survival. TAV
October 5, 2015
Patients entered into a clinical trial of TAVR and patients in two registries were evaluated for possible subclinical leaflet thrombosis in their bioprosthetic valves. 40% of the patients in the TAVR trial and 13% of registry patients were found to have such thrombosis. The risk was lower in patients anticoagulated with warfarin. Therpeutic antico
September 30, 2015
In an interview filmed at the 2015 STS Annual Meeting in San Diego, California, Tom Nguyen speaks with Michael Reardon, Chief of Cardiac Surgery at the Methodist DeBakey Heart & Vascular Center in Houston, TX.
September 29, 2015
Vinnie Bapat of Guys and St. Thomas’ Hospital, London, UK, discusses the Edwards FORTIS device, a transcatheter mitral valve device.
September 24, 2015
Neil Moat of the Royal Brompton Hospital, London, UK, gives a talk on transcatheter mitral valve implantation.